3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
Advertisement
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
REVB Revelation Biosciences Inc
3,672
$2.21
$0.05
(2.21%)
| Watchers | 3,672 |
| 52-Wk Low | $1.61 |
| 52-Wk High | $32.40 |
| Market Cap | $3.61M |
| Volume | 72,595.00 |
| 52-Wk High | $32.40 |
| 52-Wk Low | $1.61 |
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of GeminiBusiness Wire • 4 days ago
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...
Share to Feed
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...
Revelation Biosciences, Inc. (NASDAQ:REVB Free Report) Stock analysts at Zacks Small Cap dropped their Q1 2024 earnings per share estimates for shares of Revelation Biosciences in a...
Revelation Biosciences (NASDAQ:REVB Get Free Report) announced its quarterly earnings results on Friday. The company reported ($8.33) earnings per share (EPS) for the quarter, beating the...
Revelation Biosciences Inc. (REVB) has disclosed a new risk, in the Regulation category. Revelation Biosciences Inc. faces significant risk due to...
Revelation Biosciences, Inc. (NASDAQ: REVB) (the Company or Revelation), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...
Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...
Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...
Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...
Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), announced today that, as part of a limited number of accepted abstract authors, the company was invited to give an oral...